PPD and Taijitu form MAb discovery JV
PPD and Taijitu Biologics have launched a new joint venture to help drugmakers develop the next generation of monoclonal antibody (MAb) drugs.
Drugmakers will make ‘aggressive changes’ to R&D this year, say researchers
Drug developers are “aggressively changing” research and development (R&D) methods in the pursuit of the next blockbuster, according to the Tufts Centre for the Study of Drug Development (Tufts CSDD).
Spectrum & Viropro to develop rituximab biosimilar
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
Bayer injects €35m in biologics project expansion
Bayer HealthCare is investing €35m ($47m) in a new centre for the biotechnological production of ‘innovative’ pharmaceuticals to be used in clinical trials.
ProJect Pharmaceutics opens Munich HQ and begins operations
ProJect Pharmaceutics has opened its Munich headquarters and laboratory facilities in Martinsreid, Germany, beginning business operations to transform proteins, peptides and small molecules into novel drugs.
Vical hails universal vaccine adjuvant in research review
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
Takeda & Baxter aim to set up cell culture site in Japan
Takeda is collaborating with Baxter to establish a Vero cell-based influenza manufacturing facility in Japan and launch vaccines in the country.
Advinus brings services using Corning Epic to India
Advinus Therapeutics is to use Corning Epic label-free detection to provide clients in India and abroad with biologically relevant drug discovery data.
Lanxess opens Indian IER to meet demand for ultra pure water
Lanxess has opened an ion exchange resin production facility in India to cater for growing pharmaceutical manufacturing sector demand for ultrapure water.
Recognition of glass vial quality issues is supporting interest in West’s analytical capabilities and Crystal Zenith (CZ) products, new sizes of which are being developed, said a company VP.
Quintiles, London Genetics ink personalised medicine deal
Quintiles and London Genetics will offer pharmacogenetics solutions to the biopharma industry after collaborating to help advance personalised medicine.
Molecular Profiles expands into early-development
UK contract research organization (CRO) Molecular Profiles says speed to clinical is key demand driver for drug development sector.
Appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences.
EMD Millipore launches enhanced Mobius 3L CellReady Bioreactor
German pharmaceutical giant Merck's life science division, EMD Millipore, has launched its 'single-use' Mobius 3L CellReady Bioreactor, for use in the development and optimisation of cell culture processes.
Icon inks Proteome deal to bolster biomarker offering
Icon is adding protein and peptide profiling to its biomarker capabilities through a strategic alliance with Proteome Sciences.
Eden Biodesign becomes cGMP provider for PER.C6 technology
Crucell and Eden Biodesign have entered into an agreement that sees Eden become a provider of services of contract manufacturing services for Crucell's PER.C6 cell-line technology.
Novartis’ ‘smart-pill’ may be ‘watching you’ by 2012
Novartis says it plans to submit its microchip containing ‘smart-pill’ technology to European regulators within 18 months.
ATMI acquires Artelis in ‘disposables’ deal
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
Epistem inks preclinical testing deal with NIH-funded project
An NIH funded radiation countermeasure programme has extended its preclinical testing services contract with Epistem for up to five years.
B. Braun recalls heparin after OSCS detected
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Lonza boosts capacity use but tough regulators add volatility
Lonza is seeing increased capacity utilisation and project pipelines in custom manufacturing but warned more stringent regulatory approval is creating volatility.
Biocon investing $161m in Malaysian biomanufacturing site
India-based Biocon is investing RM500m ($161m) in Malaysia to establish a cGMP biomanufacturing and R&D facility.
West adds 1ml Daikyo Crystal Zenith syringe
West has launched the Daikyo Crystal Zenith 1ml long insert needle syringe system to meet demand for break-resistant delivery options.
ATMI and Austar open packaging materials plant in China
ATMI opens new packaging plant in China; positions for growth of bioprocess business in Asia and sees modest growth of life sciences business in Q3.
USDA backs Unilife’s US HQ construction
Unilife wins US Department of Agriculture (USDA) as guarantor for new manufacturing facility and global headquarters in York, Pennsylvania, US.
PBS-Bio inks deals to speed up cancer drug development
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon and Cylene to better patient selection in cancer drug development deal
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
Reaxa spin-off ADC Biotechnology talks new processing tech
A developmental purification system for Antibody-Drug-Conjugates will be launched by ADC Biotechnology (ADBC), a spin off from Reaxa, which promises reduced manufacturing costs for “magic bullet” cancer drugs.
FDA cGMP warning letters round up
in-PharmaTechnologist presents a round up of cGMP related warning letters issued by the FDA this week.
Southern Research gains bioanalytical lab assets in BioCryst acquisition
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Cell Biosciences ‘converge’ in $12m acquisition.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
SGS aims to lead biologics testing by 2014
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
CRL expands cancer model offering with p53 and BCrp rats
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Stemedica & AnC form stem cell production joint venture
Stemedica and AnC Bio have formed a joint venture to manufacture stem cells for the treatment of ischemic stroke and other degenerative disorders.
European Centre for Chirality to open in December
New ‘chiral center’ in Belgium promises to help drug firms comply with regulatory demands for quality and accelerate registration of new compounds.
Halozyme to cut workforce 25% and focus on drug delivery partnerships
Halozyme Therapeutics will cut its workforce 25 per cent to focus on strategic alliances and development of most advanced in-house candidates.
SoluBest and Dr Reddy’s ink formulation development deal
SoluBest and Dr Reddy’s Laboratories are joining forces to develop a proprietary formulation of one of SoluBest’s pipeline compounds using its Solumer platform.
NIAID awards $15.5m to needle-free dengue vaccine
Inviragen and PharmaJet have been awarded a $15.5m (€11.1m) contract by the US NIAID to develop a needle-free dengue vaccine.
“Musty odour” caused Pfizer to recall 191,000 bottles of Lipitor
Pfizer says low levels of 2,4,6 tribromoanisole were detected in seven lots of the cholesterol buster, Lipitor, that it recalled in August.
SAFC has completed the expansion of its manufacturing plant in Jerusalem, Israel, further increasing its global footprint.
Horizon aquires Hypoxium to unleash new oncology CRO
Horizon Discovery has acquired Hypoxium and launched Horizon Discovery Services, to provide “a new wave” in oncology drug development.
China's API players have bright 'potential future'
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Piramal completes Grangemouth ADC expansion
Piramal Healthcare says expanded antibody drug conjugate (ADC) capacity will support 2011 launch of new cancer drug by US biotech partner.
Galapagos’ unit, Argenta signs $46m drug discovery deal with Janssen
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
ThromboGenics agree ten-year retinal disorder drug deal with MSD Biologics
Belgium-based biopharmaceutical company, ThromboGenics, has signed a ten-year supply agreement with MSD Biologics, to produce microplasmin for the treatment of retinal disorders.
RXi and EyeGate eye deal on non-invasive ocular RNAi delivery
RXi Pharmaceuticals and EyeGate Pharma will unite to develop non-invasive, needle-free ocular delivery of RNAi therapeutics using the EyeGate II system for the treatment of retinal disorders.
Almirall ‘hit’ it off with Evotec in ion channel agreement
Anglo-German company Evotec is joining forces with Almirall to identify small molecule modulators of an ion channel target involved in respiratory diseases.
Chemically defined supplements boost Sheffield Bio-Science's product portfolio
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
DSM seeks Asian partners; welcomes J&J Crucell takeover
DSM aims to keep pace with the rapid evolution of pharmaceutical sector through increased partnering and a focus on Asia.
EPO reengineered to cross mice BBB for neuroprotection
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.